MX2009011950A - Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr. - Google Patents
Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.Info
- Publication number
- MX2009011950A MX2009011950A MX2009011950A MX2009011950A MX2009011950A MX 2009011950 A MX2009011950 A MX 2009011950A MX 2009011950 A MX2009011950 A MX 2009011950A MX 2009011950 A MX2009011950 A MX 2009011950A MX 2009011950 A MX2009011950 A MX 2009011950A
- Authority
- MX
- Mexico
- Prior art keywords
- kit
- pyrimidine derivatives
- compositions
- kinase inhibitors
- pdgfr kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
La invención proporciona una clase novedosa de derivados de pirimidina, composiciones farmacéuticas que comprenden estos compuestos, y métodos para utilizar tales compuestos con el fin de tratar o prevenir enfermedades o trastornos asociados con una actividad de cinasa anormal o mal regulada, en particular las enfermedades o trastornos que involucren una activación anormal de las cinasas c-kit, PDGFRa y PDGFRß.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91603507P | 2007-05-04 | 2007-05-04 | |
PCT/US2008/062304 WO2008137605A1 (en) | 2007-05-04 | 2008-05-01 | Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009011950A true MX2009011950A (es) | 2009-12-11 |
Family
ID=39616606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009011950A MX2009011950A (es) | 2007-05-04 | 2008-05-01 | Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr. |
Country Status (13)
Country | Link |
---|---|
US (1) | US8268850B2 (es) |
EP (1) | EP2148874B1 (es) |
JP (1) | JP5160636B2 (es) |
KR (1) | KR101122481B1 (es) |
CN (1) | CN101687853A (es) |
AT (1) | ATE544761T1 (es) |
AU (1) | AU2008247668B2 (es) |
BR (1) | BRPI0811617A2 (es) |
CA (1) | CA2686378C (es) |
EA (1) | EA017269B1 (es) |
ES (1) | ES2381318T3 (es) |
MX (1) | MX2009011950A (es) |
WO (1) | WO2008137605A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008289135B2 (en) | 2007-08-22 | 2012-02-23 | Irm Llc | 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors |
MX2010002004A (es) | 2007-08-22 | 2010-03-11 | Irm Llc | Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones con inhibidores de cinasa. |
CL2009000400A1 (es) | 2008-02-22 | 2010-09-10 | Irm Llc | Compuestos heterociclicos derivados de 3-fenil-1,6- naftiridin-2-ona; moduladores de la actividad cinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos alergicos, trastornos autoinmunes, neoplasias, rechazo en trasplante de organos, entre otras. |
TWI490214B (zh) | 2008-05-30 | 2015-07-01 | 艾德克 上野股份有限公司 | 苯或噻吩衍生物及該等作為vap-1抑制劑之用途 |
WO2011075560A1 (en) | 2009-12-17 | 2011-06-23 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
US8759366B2 (en) | 2009-12-17 | 2014-06-24 | Merck Sharp & Dohme Corp. | Aminopyrimidines as SYK inhibitors |
JP6118794B2 (ja) | 2011-04-01 | 2017-04-19 | ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション | Axlキナーゼの阻害剤としての置換n−フェニルピリミジン−2−アミン類似体 |
US8703767B2 (en) | 2011-04-01 | 2014-04-22 | University Of Utah Research Foundation | Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors |
EP2707357B1 (en) | 2011-05-10 | 2017-01-18 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as syk inhibitors |
WO2012154518A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
RU2013154412A (ru) | 2011-05-10 | 2015-06-20 | Мерк Шарп И Доум Корп. | Аминопиримидины в качестве ингибиторов syc |
US9296703B2 (en) | 2012-10-04 | 2016-03-29 | University Of Utah Research Foundation | Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors |
EP2903972B1 (en) | 2012-10-04 | 2019-12-04 | University of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
CN105142624A (zh) | 2013-01-10 | 2015-12-09 | 普尔莫凯恩股份有限公司 | 非选择性激酶抑制剂 |
ES2738493T3 (es) | 2013-03-14 | 2020-01-23 | Tolero Pharmaceuticals Inc | Inhibidores de JAK2 y ALK2 y métodos para su uso |
CN104458674A (zh) * | 2013-09-12 | 2015-03-25 | 中国药科大学 | 一种筛选血管内皮生长因子1激酶抑制剂高通量筛选方法 |
AU2014331796B2 (en) | 2013-10-11 | 2020-05-07 | Gilead Sciences, Inc. | Spray dry formulations |
BR112019008622A2 (pt) | 2016-10-27 | 2019-07-09 | Pulmokine Inc | método para tratar uma condição |
AU2019223911A1 (en) * | 2018-02-21 | 2020-07-23 | Melior Pharmaceuticals I, Inc. | Treatment of liver diseases |
US11013741B1 (en) | 2018-04-05 | 2021-05-25 | Sumitomo Dainippon Pharma Oncology, Inc. | AXL kinase inhibitors and use of the same |
CA3103995A1 (en) | 2018-07-26 | 2020-01-30 | Sumitomo Dainippon Pharma Oncology, Inc. | Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same |
TWI759829B (zh) * | 2019-08-23 | 2022-04-01 | 財團法人生物技術開發中心 | 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物 |
CN112745300A (zh) * | 2021-01-21 | 2021-05-04 | 杭州浙中医药科技有限公司 | 一种制备n-(5-羧基-2-甲基苯基)-4-(3-吡啶)-2-嘧啶胺的方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0164204A1 (en) | 1984-05-12 | 1985-12-11 | FISONS plc | Novel pharmaceutically useful pyrimidines |
GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB0022438D0 (en) | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
US7122544B2 (en) | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
US7129242B2 (en) | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
US7429599B2 (en) | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
EP1395261B1 (en) | 2001-05-16 | 2006-06-28 | GPC Biotech AG | Pyridylpyrimidine derivatives as effective compounds against prion diseases |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
GB0222514D0 (en) * | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
ES2390227T3 (es) | 2004-09-09 | 2012-11-07 | Natco Pharma Limited | Nuevos derivados de fenilaminopirimidina como inhibidores de la BCR-ABL kinasa |
RU2007114080A (ru) | 2004-10-13 | 2008-11-27 | Вайет (Us) | N-бензилсульфонил-замещенные аналоги анилинопиримидина |
WO2006101977A2 (en) | 2005-03-16 | 2006-09-28 | Targegen, Inc. | Pyrimidine compounds and methods of use |
KR100674813B1 (ko) | 2005-08-05 | 2007-01-29 | 일양약품주식회사 | N-페닐-2-피리미딘-아민 유도체 및 그의 제조방법 |
CN101272685A (zh) | 2005-09-27 | 2008-09-24 | Irm责任有限公司 | 包含二芳基胺的化合物和组合物以及它们作为c-kit受体调节剂的用途 |
BRPI0811517A2 (pt) * | 2007-05-04 | 2014-11-18 | Irm Llc | Compostos e composições como inibidores de c-kit e pdgfr cinase. |
CN101720322A (zh) | 2007-05-04 | 2010-06-02 | Irm责任有限公司 | 作为c-kit和pdgfr激酶抑制剂的化合物和组合物 |
-
2008
- 2008-05-01 AT AT08747412T patent/ATE544761T1/de active
- 2008-05-01 MX MX2009011950A patent/MX2009011950A/es active IP Right Grant
- 2008-05-01 BR BRPI0811617A patent/BRPI0811617A2/pt not_active IP Right Cessation
- 2008-05-01 WO PCT/US2008/062304 patent/WO2008137605A1/en active Application Filing
- 2008-05-01 CN CN200880023078A patent/CN101687853A/zh active Pending
- 2008-05-01 AU AU2008247668A patent/AU2008247668B2/en not_active Ceased
- 2008-05-01 US US12/598,919 patent/US8268850B2/en not_active Expired - Fee Related
- 2008-05-01 ES ES08747412T patent/ES2381318T3/es active Active
- 2008-05-01 CA CA2686378A patent/CA2686378C/en not_active Expired - Fee Related
- 2008-05-01 EP EP08747412A patent/EP2148874B1/en not_active Not-in-force
- 2008-05-01 EA EA200901483A patent/EA017269B1/ru not_active IP Right Cessation
- 2008-05-01 KR KR1020097025278A patent/KR101122481B1/ko not_active IP Right Cessation
- 2008-05-01 JP JP2010507541A patent/JP5160636B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20100190811A1 (en) | 2010-07-29 |
WO2008137605A1 (en) | 2008-11-13 |
JP5160636B2 (ja) | 2013-03-13 |
EA200901483A1 (ru) | 2010-04-30 |
AU2008247668A1 (en) | 2008-11-13 |
JP2010526148A (ja) | 2010-07-29 |
KR101122481B1 (ko) | 2012-02-29 |
CA2686378A1 (en) | 2008-11-13 |
US8268850B2 (en) | 2012-09-18 |
KR20090130342A (ko) | 2009-12-22 |
EP2148874B1 (en) | 2012-02-08 |
EP2148874A1 (en) | 2010-02-03 |
AU2008247668B2 (en) | 2013-01-10 |
CA2686378C (en) | 2012-07-24 |
ES2381318T3 (es) | 2012-05-25 |
BRPI0811617A2 (pt) | 2017-06-06 |
EA017269B1 (ru) | 2012-11-30 |
CN101687853A (zh) | 2010-03-31 |
ATE544761T1 (de) | 2012-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009011950A (es) | Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
MX2009011951A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
MX2010009207A (es) | Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa. | |
MX2009004716A (es) | Compuestos y composiciones en la forma de inhibidores de quinasa de proteina. | |
MX2009011952A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
MX339937B (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit. | |
MX342329B (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit. | |
MX2014002486A (es) | Compuestos y composiciones como inhibidores de cinasa pdgfr. | |
TN2012000081A1 (en) | Compounds and compositions as protein kinase inhibitors | |
MX2009007944A (es) | Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium. | |
TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
TW200637547A (en) | Compounds and compositions as protein kinase inhibitors | |
WO2011014795A3 (en) | Compounds and compositions as syk kinase inhibitors | |
WO2009097287A9 (en) | Compounds and compositions as kinase inhibitors | |
MX2008002165A (es) | Compuestos y composiciones como inhibidores de la proteina cinasa. | |
EA201190158A1 (ru) | Производные бензофуранила для применения в качестве ингибиторов глюкокиназы | |
MX2009003456A (es) | Compuestos y composiciones como inhibidores de proteina cinasa. | |
MXPA05010711A (es) | Compuestos y composiciones novedosos como inhibidores de proteina-quinasa. | |
PL1896470T3 (pl) | Pochodne pirolopirydynowe jako inhibitory kinazy białkowej | |
AU2011269989A8 (en) | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity | |
HK1154002A1 (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
MX2009006170A (es) | Compuestos y composiciones como inhibidores de cinasa. | |
WO2012048259A3 (en) | Substituted pyridazine carboxamide compounds | |
MX2012012031A (es) | Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos. | |
WO2012048258A3 (en) | Substituted pyridazine carboxamide compounds as kinase inhibitor compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HH | Correction or change in general | ||
FG | Grant or registration |